Warning:The NCBI web site requires JavaScript to function. more...
Clioquinol: Review of its Mechanisms of Action and Clinical Uses in Neurodegenerative Disorders.
Bareggi SR, Cornelli U.
CNS Neurosci Ther. 2010 Dec 27. doi: 10.1111/j.1755-5949.2010.00231.x. [Epub ahead of print]
Related citations
[Evaluation of neurological symptoms related to hip fracture in a 29-year longitudinal study of subacute myelo-optic-neuropathy (SMON)].
Konagaya M, Kuru S, Konagaya Y.
Nippon Ronen Igakkai Zasshi. 2010;47(5):445-51. Japanese.
[The history of adverse drug reactions, relief for these health damage and safety measures in Japan].
Takahashi H.
Yakushigaku Zasshi. 2009;44(2):64-70. Japanese.
Copper deficiency myeloneuropathy: a clue to clioquinol-induced subacute myelo-optic neuropathy?
Schaumburg H, Herskovitz S.
Neurology. 2008 Aug 26;71(9):622-3. No abstract available.
Metals in our minds: therapeutic implications for neurodegenerative disorders.
Doraiswamy PM, Finefrock AE.
Lancet Neurol. 2004 Jul;3(7):431-4. Review.
Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol.
Yassin MS, Ekblom J, Xilinas M, Gottfries CG, Oreland L.
J Neurol Sci. 2000 Feb 1;173(1):40-4.
Clioquinol-zinc chelate: a candidate causative agent of subacute myelo-optic neuropathy.
Arbiser JL, Kraeft SK, van Leeuwen R, Hurwitz SJ, Selig M, Dickersin GR, Flint A, Byers HR, Chen LB.
Mol Med. 1998 Oct;4(10):665-70.
Free full text Related citations
Transmethylation reactions and autoradiographic distribution of vitamin B12: effects of clioquinol treatment in mice.
Yassin MS, Ekblom J, Löfberg C, Oreland L.
Jpn J Pharmacol. 1998 Sep;78(1):55-61.
Aconite induced myelo-optic neuropathy in a rabbit model.
Suk KD, Yoon KC, Shin JP, Kim SH.
Korean J Ophthalmol. 1994 Dec;8(2):77-82.
Myelo-optic neuropathy caused by aconitine in rabbit model.
Kim SH, Kim SD, Kim SY, Kwak JS.
Jpn J Ophthalmol. 1991;35(4):417-27.
Subacute myelo-optic neuropathy (SMON) induced by antituberculous treatment in uraemia.
Donati E, Bargnani C, Besana R, Locatelli P, Faggi L, De Marinis S.
Funct Neurol. 1990 Apr-Jun;5(2):151-4. No abstract available.
[Neuromyeloencephalopathy caused by high-dose muzolimine medication in patients with renal failure].
Pohlmann-Eden B, Berlit P, Holle A, Kaschel H, Gretz N.
Fortschr Neurol Psychiatr. 1990 Mar;58(3):87-97. German.
[Our experiences of PISCES (percutaneously inserted spinal cord electrical stimulation) in SMON and other neurologic disorders].
Tani S, Shimizu H, Ishijima B, Hanakago R.
No To Shinkei. 1984 Apr;36(4):383-8. Japanese.
[A case of myelo-optic neuropathy preceded by abdominal symptoms].
Massons Cirera J, Zunzunegui Costas J, Titus Alvareda F.
Med Clin (Barc). 1983 Jun 4;80(20):894-5. Spanish.No abstract available.
The use of vital and morbidity statistics for the detection of adverse drug reactions and for monitoring of drug safety.
Stolley PD.
J Clin Pharmacol. 1982 Nov-Dec;22(11-12):499-504.
Subacute myelo-optic neuropathy is not a special form of multiple sclerosis.
Kono R, Kuroiwa Y.
Lancet. 1982 Jul 31;2(8292):267. No abstract available.
Subacute myelo-optic neuropathy (SMON). First neuro-pathological report outside Japan.
Ricoy JR, Ortega A, Cabello A.
J Neurol Sci. 1982 Feb;53(2):241-51.
Zinc deficiency, acrodermatitis enteropathica, optic atrophy, subacute myelo-optic neuropathy, and 5,7-dihalo-8-quinolinols.
Sturtevant FM.
Pediatrics. 1980 Mar;65(3):610-3.
Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.
Baumgartner G, Gawel MJ, Kaeser HE, Pallis CA, Rose FC, Schaumburg HH, Thomas PK, Wadia NH.
J Neurol Neurosurg Psychiatry. 1979 Dec;42(12):1073-83.
[Subacute myelo-optic-neuropathy during treatment with chloro-iodo-hydroxyquinoleine (author's transl)].
Charasz N, Vacherot B, Dougados M, Bousser MG, Belaiche J, Cattan D.
Gastroenterol Clin Biol. 1979 Apr;3(4):371-4. French.No abstract available.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on